

Tables

Table 1. Survival at day 49 after 3LL injection

<i>DS</i>	<i>live mice</i>	<i>dead mice</i>	<i>survival (%)</i> *	<i>p-value</i>
DS Po912	11	5	68.75	0.0003
DS Po821	7	9	43.75	0.014
DS 1020	8	8	50	0.005
DS 9267	7	9	43.75	0.014
DS 9517	7	9	43.75	0.014
DS 8892	4	12	25	0.14
DS 8767	8	8	50	0.005
DS 0895	7	9	43.75	0.014
DS 1145	10	6	62.5	0.0008
PBS (control)	1	15	6.2	

* survival (%) = [live mice/total mice] x 100





Table 2. **Weights of lungs at day 50 after 3LL injection**

Treatment with DS	Weights \pm SD (gr.)	Decrease (%) *
DS Po912	0.37 ± 0.17	60.1
DS Po821	0.28 ± 0.07	69.3
DS 1020	0.28 ± 0.13	69.8
DS 9267	0.51 ± 0.07	44.8
DS 9517	0.43 ± 0.13	53.0
DS 8892	0.66 ± 0.18	28.8
DS 8767	0.44 ± 0.08	52.2
DS 0895	0.49 ± 0.14	46.7
DS 1145	0.59 ± 0.18	36.4
PBS	0.92	

* Decrease (%) = $[1 - (\text{weights of treated group} / \text{weights of control group})] \times 100$


APPENDIX OF STRUCTURES

List of Heparin and Heparan sulfate Disaccharides


<p>Po912 Sigma H 9392, (α-ΔUA-2S-[1\rightarrow4]-GlcNS), produced by the action of heparinase I and II on heparin.</p>	
<p>Po821 Our novel DS, Synthetic, (GlcNS,6S-[1\rightarrow4]-GlcA-2S), produced by the action of heparanase on heparan sulfate.</p>	
<p>DS 1020 Sigma H 1020, (α-ΔUA-[1\rightarrow4]-GlcNS-6S), produced by the action of heparinase II on heparin.</p>	
<p>DS 9267 Sigma H 9267, (α-ΔUA-2S-[1\rightarrow4]-GlcNS-6S), produced by the action of heparinase I and II on heparin.</p>	

DS 9517


Sigma H 9517,
(α - Δ UA-2S-[1 \rightarrow 4]-GlcNAc-6S),
produced by the action of heparinase II on
heparin.

**DS 8892,**


Sigma H 8892,
(α - Δ UA-2S-[1 \rightarrow 4]-GlcN-6S),
produced by the action of heparinase on
heparin.

**DS 8767**

Sigma H 8767,
(α - Δ UA-2S-[1 \rightarrow 4]-GlcNAc),
produced by the action of heparinase II on
heparin.


**DS 0895**

Sigma H 0895,
(α - Δ UA-[1 \rightarrow 4]-GlcNAc),
produced by the action of heparinase II and
III on heparin.



DS 1145

Sigma H 1145,
(α - Δ UA-[1 \rightarrow 4]-GlcNS),
produced by the action of heparinase II and
III on heparin.



Abbreviation:

Δ UA = 4-deoxy α -L-threo-hex-4-enopyranosyluronic acid.


GlcA = β -D-glucopyranoside uronic acid.

GlcN = D-glucosamine.

Ac = Acetyl.

NS, 2S, 6S, = N-sulfo, 2-sulfate and 6-sulfate respectively.

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ Scanned copy is best available. 1) There are 11 pages of drawings. Not 17.
2) Figures 4, 15 are dark